Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Last Updated: February 7, 2023

Details for Patent: 8,791,154

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,791,154 protect, and when does it expire?

Patent 8,791,154 protects PATADAY ONCE DAILY RELIEF and is included in one NDA.

This patent has thirty patent family members in nineteen countries.

Summary for Patent: 8,791,154

Title:	High concentration olopatadine ophthalmic composition
Abstract:	The present invention is an ophthalmic composition containing a relatively high concentration of olopatadine. The composition is typically an ophthalmic aqueous solution containing relatively high concentrations of olopatadine solubilized within the solution. The composition is preferably capable of providing enhanced relief from symptoms of ocular allergic conjunctivitis, particularly late phase symptoms of ocular allergic conjunctivitis.
Inventor(s):	Gamache; Daniel A. (Arlington, TX), Alani; Laman (Fort Worth, TX), Ghosh; Malay (Fort Worth, TX), Galan; Francisco Javier (Barcelona, ES), Perdiguer; N ria Carreras (Barcelona, ES), Singh; Onkar N. (Arlington, TX)
Assignee:	Alcon Research, Ltd. (Fort Worth, TX)
Application Number:	13/475,607
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,791,154
Patent Claim Types: see list of patent claims	Use; Formulation; Compound;

Drugs Protected by US Patent 8,791,154

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Alcon Labs Inc	PATADAY ONCE DAILY RELIEF	olopatadine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	206276-001	Jan 30, 2015		OTC	Yes	Yes	See Plans and Pricing	See Plans and Pricing	Y			TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS	See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 8,791,154

Subscribe to access the full database, or Try it Free
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	086490	See Plans and Pricing
Australia	2012255046	See Plans and Pricing
Brazil	112013022057	See Plans and Pricing
Canada	2826725	See Plans and Pricing
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Harvard Business School

McKesson

Boehringer Ingelheim

Dow

McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.